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Pregnant women (and their fetuses) are treated with a significant number of prescription
and non-prescription medications. Interactions among those drugs may affect their effi-
cacy and toxicity in both mother and fetus. Whereas interactions that result in altered drug
concentrations in maternal plasma are detectable, those involving modulation of placen-
tal transfer mechanisms are rarely reflected by altered drug concentrations in maternal
plasma. Therefore, they are often overlooked. Placental-mediated interactions are possi-
ble because the placenta is not only a passive diffusional barrier, but also expresses a
variety of influx and efflux transporters and drug-metabolizing enzymes. Current data on
placental-mediated drug interactions are limited. In rodents, pharmacological or genetic
manipulations of placental transporters significantly affect fetal drug exposure. In contrast,
studies in human placentae suggest that the magnitude of such interactions is modest in
most cases. Nevertheless, under certain circumstances, such interactions may be of clini-
cal significance.This review describes currently known mechanisms of placental-mediated
drug interactions and the potential implications of such interactions in humans. Better
understanding of those mechanisms is important for minimizing fetal toxicity from drugs
while improving their efficacy when directed to treat the fetus.
Keywords: placenta, pregnancy, maternal-fetal pharmacology, drug interactions, P-glycoprotein, breast cancer
resistance protein, organic cation transporters
INTRODUCTION
Pregnant women (and their fetuses) are exposed to a signifi-
cant number of prescription and non-prescription medications.
In North America, women use an average of 2.3 prescription med-
ications during pregnancy, but many consume four drugs or more
(Mitchell et al., 2011). Often, these drugs are taken throughout
pregnancy, for the treatment of chronic diseases, such as hyperten-
sion, asthma, and epilepsy. As the pregnancy rates among women
40 years of age and older have been steadily increasing (Ventura
et al., 2008), the mean number of drugs used by a pregnant woman
is expected to increase in future years. Those polytherapeutic reg-
imens may result in drug–drug interactions (DDIs) that affect the
mother, the fetus, or both. DDIs that involve the fetus can result
from changes in plasma concentrations (unbound or total) of at
least one of the interacting drugs, changes in drug’s disposition
or effects within the fetus, or a combination of the two. A third
source for altered fetal effects of drugs resides in the interfaces
between plasma and the fetus, namely the placenta. As with sev-
eral other distributional DDIs, placental-mediated DDIs may be
rarely reflected by altered drug concentrations in maternal plasma,
especially when only a small fraction of the total amount of drug
in the body distributes into the fetus (Endres et al., 2006).
Abbreviations: ABC, adenosine triphosphate binding cassette; AUC, area under
the concentration-time curve; BBB, blood-brain barrier; BCRP, breast cancer resis-
tance protein; CsA, cyclosporine A; DDI, drug-drug interaction; MDR, multidrug
resistance protein; MRP, multidrug resistance-associated protein; OATP, organic
anion transporting polypeptide; OCT, organic cation transporter; OCTN, organic
cation/carnitine transporter; P-gp, P-glycoprotein; SLC, solute carrier.
By modulating placental function, a drug can potentially affect
the distribution of another drug into the fetus, its removal from
the fetus, or both. These changes may be of clinical relevance,
because the outcomes of in utero exposure to medications may
vary from benign to structural and behavioral teratogenicity and
termination of pregnancy, and are often unknown.
THE PLACENTAL BARRIER
The feto-placental-maternal circulation is established around the
10th week of pregnancy. The placenta then becomes a permeability
boundary which regulates the exchange of nutrients and metabo-
lites between mother and fetus (van der Aa et al., 1998). Within
the placenta, the barrier between maternal and fetal circulations
consists of trophoblast cells and to some extent the endothelium
of fetal capillaries. As the pregnancy proceeds, the cytotrophoblast
layer partially disappears. Consequently, the trans-placental diffu-
sion distance decreases, increasing placental permeability. Trans-
port across the placenta then becomes greatly regulated by the two
membranes of the syncytiotrophoblast, the syncytial microvillous
membrane at the maternal side, and the basal membrane at the
fetal side (van der Aa et al., 1998).
The placental barrier can limit the delivery of drugs targeted
to treat the fetus, or given to prevent maternal-to-fetal disease
transmission, such as in the case of anti-HIV-protease inhibitors
(Endres et al., 2006). At the same time, the barrier may protect the
fetus against the effect of noxious compounds. An example is the
chemotherapeutic agent doxorubicin, which has been safely used
in pregnancy (Cardonick and Iacobucci, 2004). Yet, most drugs
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that enter the maternal circulation can cross the placenta to some
extent (Unadkat et al., 2004). Passive diffusion is the predominant
route by which drugs cross the placenta, and applies to molecules
of less than 600 Da, which are hydrophobic and non-ionized. How-
ever, an important role for membrane transporters in placental
drug transfer is being increasingly recognized (Figure 1). Phago-
cytosis and pinocytosis have not so far been shown to significantly
contribute to placental drug transfer (Ni and Mao, 2011). Of note,
drugs which diffuse rapidly across the placenta may display blood
flow-limited transfer kinetics, and their delivery to the fetus may
be affected by medications which alter placental blood flow. In
addition, developmental changes in the placenta that occur dur-
ing pregnancy, such as reduced trophoblast thickness, increased
surface area and enhanced placental blood flow, may alter the
rate of trans-placental diffusion over pregnancy (Unadkat et al.,
2004).
PLACENTAL DRUG-METABOLIZING ENZYMES
The placenta expresses a variety of xenobiotic-metabolizing
enzymes from the earlier stages of pregnancy. However, com-
pared to the liver, placental drug metabolism seems to be relatively
minor and does not significantly limit the extent of drug delivery
to the fetus. On the other hand, placental enzymes can catalyze
the formation of reactive metabolites that might be fetotoxic
(Pasanen and Pelkonen, 1994). Drugs which have been shown
to undergo significant placental metabolism include azidothymi-
dine, dexamethasone, and prednisolone (van der Aa et al., 1998).
The anticonvulsant oxcarbazepine (but not carbamazepine) is also
metabolized to some extent by the human placenta (Pienimäki
et al., 1997; Myllynen et al., 1998).
Placental enzymes catalyze phase I (drug oxidation, reduc-
tion, and hydrolysis) and Phase II (conjugation) reactions. Among
phase I enzymes proteins which have been identified in the pla-
centa are cytochrome P450 (CYP) 1A1, 2E1, 3A4, 3A5, 3A7,
4B1, and 19 (Syme et al., 2004; Myllynen et al., 2009). At the
mRNA level, the major isoforms expressed are placental aro-
matase (CYP19) and CYP11A (Nishimura et al., 2003). Placental
CYP19 is involved in the metabolism of several drugs, including
the antidiabetic agent glyburide (Zharikova et al., 2009) and the
opioids buprenorphine (Deshmukh et al., 2003) and methadone
(Nanovskaya et al., 2004). Furthermore, methadone may act as
a potent inhibitor of CYP19 in vivo, thus potentially interfering
with steroid hormone metabolism and drug detoxification (Desh-
mukh et al., 2003; Lu et al., 2010). In mothers treated with the
glucocorticoid betamethasone, placental CYP19 mRNA content
and aromatase activity were significantly lower than in controls
(Paakki et al., 2000). Whether these changes affect placental drug
metabolism and fetal exposure to drugs and their metabolites is
currently unknown.
The most established placental phase II enzymes with regard
to xenobiotic metabolism are uridine diphosphate glucuronosyl-
transferases (UGTs). For example, in the trans-placental perfusion
model, 17% of the antipsychotic drug olanzapine was conjugated
to the N -glucuronide (Schenker et al.,1999). Other placental phase
II enzymes include glutathione S-transferase, epoxide hydrolase,
N -acetyltransferase, and sulfotransferases.
The type and the amount of drug-metabolizing enzymes
change over gestation. In general, more CYP isozymes are
expressed in the first trimester, when the fetus is more suscep-
tible to the effects of teratogens, than at term (Hakkola et al.,
1996). In contrast, UGTs are present at the placental metabolic
barrier throughout pregnancy. Placental xenobiotic-metabolizing
activities are affected by a variety of maternal and environmental
factors, including drug abuse, smoking, alcohol consumption, pol-
luted air, and contaminated food (Stejskalova and Pavek, 2011).
For example, UGT and CYP1A activities are significantly ele-
vated in placentae of mothers who smoke and are greatest in
women who both smoke and consume alcohol (Collier et al.,
2002b). In rats, treatment with the anticonvulsant phenobarbi-
tal induced placental CYP3A1 (Ejiri et al., 2005a) but did not
affect the expression of phase II enzymes (Ejiri et al., 2005b).
To our knowledge, no significant DDIs which involve placen-
tal phase II enzymes have been reported so far. However, the
presence of UGTs at the placental metabolic barrier throughout
gestation implies a major role for them in xenobiotic detox-
ification (Collier et al., 2002a). Their modulation is therefore
expected to affect the amount of substrate drugs transferred to
the fetus.
FIGURE 1 | A schematic representation of the syncytioblast. Free drugs
and their metabolites usually cross the placenta by passive diffusion,
transporter-mediate transfer, or both. Within the syncytium, drugs can
undergo phase I and phase II metabolism. P-gp, P-glycoprotein; BCRP, breast
cancer resistance protein; MRP, multidrug resistance-associated protein;
OATP, organic anion-associated polypeptide; OAT, organic anion transporter;
OCT, organic cation transporter; OCTN, organic cation/carnitine transporters;
SERT, serotonin transporter; NET, norepinephrine transporter; ENT,
equilibrative nucleoside transporter; CYP, cytochrome P450; UGT, uridine
diphosphate glucuronosyltransferases.
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PLACENTAL TRANSPORTERS
Placental transporters mediate the uptake of hormones and nutri-
ents from maternal blood into the fetus and the substrate removal
back to maternal blood. Transporters therefore may contribute to
the barrier which protects the fetus from toxins and teratogens.
Furthermore, placental transporters take part in the homeostasis
of placental tissue itself (Ganapathy, 2011; Ni and Mao, 2011).
Uptake transporters facilitate substrate influx into the syncytium
and fetal capillary cells, whereas efflux transporters export their
substrates from cells, although some transporters can exhibit bidi-
rectional substrate transport. For many drugs, the net transfer
across the placenta may be determined by interplay between sev-
eral transport systems which can operate in the same direction or
opposite directions. Furthermore, the impact of a transporter on
substrate transfer across the placenta would not be substantial if
the substrate undergoes extensive trans-placental diffusion.
Two major superfamilies of transporters are present in the
placenta, adenosine triphosphate binding cassette (ABC), and
solute carrier (SLC) transporters (Vähäkangas and Myllynen,
2009; Prouillac and Lecoeur, 2010). This section will focus on
transporters which have been reported or are likely to be involved
in DDIs at the placenta.
Transporters of the adenosine triphosphate binding cassette
superfamily
Adenosine triphosphate binding cassette transporters are primary
active transporters which function to remove substrates from cells.
Most of the recognized placental ABC transporters are located
at the maternal-facing (apical) brush border membrane of the
syncytiotrophoblast (Figure 1). There, they play a major role in
decreasing the fetal exposure to drugs and other xenobiotics (Ni
and Mao, 2011). The most abundant ABC transporters on the
apical membrane of syncytiotrophoblasts, and likely the most clin-
ically relevant ones, are P-glycoprotein (P-gp) and the breast cancer
resistance protein (BCRP; Vähäkangas and Myllynen, 2009). The
multidrug resistance proteins (MRPs) 1–3 and 5 have also been
identified in the human placenta (Ni and Mao, 2011).
P-glycoprotein. P-gp (MDR1), which is expressed at the api-
cal membrane of syncytiotrophoblasts, is encoded by the ABCB1
gene (Ceckova-Novotna et al., 2006). In rodents, two correspond-
ing multidrug resistance proteins are encoded by the mdr1a and
mdr1b genes (Schinkel et al., 1997). P-gp substrates are gener-
ally hydrophobic molecules, of which many are cationic. Substrate
drugs include HIV-protease inhibitors, immunosuppressive drugs,
and antibiotics. P-gp activity can be inhibited by therapeutic
compounds, including those administered to pregnant women
such as the immunosuppressant cyclosporine A (CsA) and the
cardiovascular agent verapamil (Unadkat et al., 2004).
The role of P-gp in protecting the fetus from potential ter-
atogens was first demonstrated in CF-1 mice, that are naturally
deficient of mdr1a. Dams were exposed to an isomer of the pesti-
cide avermectin, a P-gp substrate known to produce cleft palate in
mice. Fetuses homozygous for P-gp deficiency were 100% suscepti-
ble to cleft palate, whereas in heterozygote fetuses the incidence of
this malformation was 30%. The homozygous wild-type fetuses
were insensitive to avermectin at the doses tested (Lankas et al.,
1998). Further evidence for the protective role of P-gp was pro-
vided by Smit et al. (1999). Mdr1a/b+/− heterozygous females
were mated with heterozygous males. Intravenous administration
of 3H-digoxin, 14C-saquinavir, and paclitaxel to the dams resulted
in 2.4-, 7-, and 16-fold greater concentrations, respectively, of
the administered drug in Mdr1a/b−/− fetuses than in their wild-
type siblings. In the same study, oral administration of the P-gp
inhibitors valspodar or elacridar to pregnant Mdr1a/b+/+ mice
produced similar increases in drug distribution to that observed
in Mdr1a/b−/− fetuses, indicating that placental P-gp can be com-
pletely inhibited in mice by pharmacological means. In perfused
rat placentae, coadministration of CsA with quinidine or chlor-
promazine resulted in 1.7- and 1.9-fold increases, respectively, in
CsA concentration in the fetal compartment (Pávek et al., 2001).
More recently, positron imaging tomography (PET) was used
to study the contribution of placental P-gp to fetal protection
in vivo in a more representative model, the non-human primate.
11C-verapamil and CsA were used as the model P-gp substrate
and inhibitor, respectively. In this study, the significance of pla-
cental P-gp was demonstrated by the 2.2-fold increase in fetal liver
radioactivity after CsA administration during late pregnancy (Eyal
et al., 2009). Of note, maternal plasma concentrations of CsA were
greater compared to those achieved in clinic. Additionally, in this
study and in those conducted in mice, the impact of transporter
inhibition at the placenta was consistently less, compared to that
observed at the blood-brain barrier (Figure 2; based on studies
conducted by Eyal et al., 2009).
In the dually perfused human placenta model, P-gp inhibi-
tion increased the maternal-to-fetal transfer of the HIV-protease
inhibitors saquinavir (Mölsä et al., 2005), indinavir, and lopinavir
(Ceccaldi et al., 2009; Table 1). Consistent with those observa-
tions, the cord-to maternal concentration ratios of indinavir and
saquinavir are extremely low, and that of lopinavir is lesser than
FIGURE 2 |Three dimensional projections of PET images of
11C-verapamil radioactivity in pregnantMacaca nemestrina before (A)
and during (B) administration of cyclosporine A (CsA; 12mg/kg/h).
Fetal liver was the reporter of 11C-radioactivity that crossed the placental
barrier. Because of P-gp inhibition, CsA significantly increased the
distribution of 11C-radioactivity into fetal liver. Thus, the fetal liver is seen in
the figure only in B (indicated by yellow arrows). MH, maternal head; MK,
maternal kidneys; ML, maternal liver; UW, uterine wall. Based on studies
conducted by Eyal et al. (2009).
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one (Hutson et al., 2011). Further studies demonstrated a role
for P-gp in the maternal-to-fetal transfer of the chemotherapeutic
agent paclitaxel, the opioid methadone (Nanovskaya et al., 2005),
and the beta-blocker talinolol (May et al., 2008; Table 1). Moreover,
in human placental membrane vesicles, methadone, buprenor-
phine, and morphine competitively inhibited paclitaxel transport
(Hemauer et al., 2009). In contrast, in perfused term placentae,
maternal-to-fetal transfer of digoxin was not affected by quinidine
or verapamil (Holcberg et al., 2003).
P-gp has been detected in syncytiotrophoblast cells through-
out gestation. However, expression of P-gp mRNA and protein
decreases with gestational age (Ni and Mao, 2011). The exact
factors which regulate P-gp expression have not been identified,
although a role has been suggested for estrogen, progesterone, glu-
cocorticoids, and various cytokines (Ni and Mao, 2011). Indeed,
in animal models, the synthetic glucocorticoids betamethasone
(Kalabis et al., 2009) and dexamethasone (Petropoulos et al., 2010)
affected placental P-gp expression, although changes in P-gp pro-
tein expression did not translate into altered placental transfer of
3H-digoxin (Petropoulos et al., 2010). Interestingly, P-gp expres-
sion in term placentae was greater in HIV-1-infected women
receiving pharmacotherapy than in uninfected controls (Camus
et al., 2006).
The breast cancer resistance protein. Similar to P-gp, placental
BCRP has been localized to the brush border membrane of syn-
cytiotrophoblast cells (Figure 1). In addition, BCRP is expressed
on the luminal (fetal-facing) surface of placental capillaries (Ni
and Mao, 2011). BCRP substrates include many drugs used dur-
ing pregnancy, such as nitrofurantoin and glyburide (Ni and Mao,
2011). Some BCRP substrates are also substrates of P-gp and MRPs
(Ni and Mao, 2011). Importantly, HIV-protease inhibitors are not
transported by BCRP. Instead, drugs of this class, such as ritonavir,
saquinavir, and nelfinavir, are effective BCRP inhibitors (Gupta
et al., 2004). Other BCRP inhibitors which may be used by preg-
nant women include CsA (Gupta et al., 2006) and omeprazole
(Breedveld et al., 2004). Unlike P-gp, the data about the expres-
sion levels of BCRP in the placenta throughout gestation are not
consistent (Ni and Mao, 2011).
In P-gp deficient pregnant mice (to avoid confounding drug
transport by P-gp) orally treated with elacridar, fetal penetration
of topotecan increased twofold, compared to wild-type controls
(Jonker et al., 2000). Similarly, studies with Bcrp1−/− pregnant
mice treated with glyburide (Zhou et al., 2008) and nitrofu-
rantoin (Zhang et al., 2007) demonstrated 2.3- and 5.0-fold
increase, respectively, in the fetal/maternal drug concentration
ratio compared to wild-type fetuses. In the perfused human pla-
centa model, the BCRP inhibitor nicardipine increased 1.8-fold the
fetal-to-maternal concentration ratio of glyburide (Pollex et al.,
2008).
Multidrug resistance-associated proteins. Multidrug resistance
proteins are predominantly organic anion transporters but in
addition transport neutral organic compounds. The substrate and
inhibitor selectivity of individual MRPs may partially overlap with
that of other MRPs, P-gp, BCRP, and organic anion transporters
(Hagenbuch and Meier, 2004; Ni and Mao, 2011). Unlike P-gp and
BCRP, knowledge on the functional significance of placental MRPs
is relatively poor, and data related to potential MRPs-mediated
placenta DDIs are currently available for MRPs 1 and 2 only.
Multidrug resistance protein 1 is predominantly expressed on
fetal blood vessel endothelia and the basal membrane of the
term human syncytiotrophoblast (Figure 1). Some expression
has also been detected at the apical layer of syncytiotrophoblasts
(St-Pierre et al., 2000). In BeWo trophoblast cells, CsA, a P-gp, and
MRP1 inhibitor, increased the net apical-to-basolateral transfer of
Table 1 | Effect of transporter inhibition on drug transfer across perfused term human placentae.
Transporter Drug
(concentration)
Inhibitor
(concentration)
Fold change in
maternal-to-fetal
transfer in inhibitor-
treated vs. control
placentae(P)a
Fold change in fetal-to-
maternal transfer
in inhibitor-treated
vs. control
placentae (P)a
Reference
P-gp Saquinavir (6.7µg/mL) PSC833 (2.4µg/mL) 3.5 (<0.01) 0.7 (>0.05) Mölsä et al. (2005)
GF120918 (0.6µg/mL) 3.0 (<0.01) ND
Indinavir (7.6µg/mL) PSC833 (1.2µg/mL) 1.5 (<0.05) ND Sudhakaran et al. (2008)
Ritonavir (0.22µg/mL) 1.1 (>0.05) ND
Lopinavir (6µg/mL) CsA (12.0µg/mL) 10.3 (<0.05) ND Ceccaldi et al. (2009)
Talinolol (0.29µg/mL) Verapamilb (13.6µg/mL) 1.2 (<0.05) ND May et al. (2008)
PSC833 (2.2µg/mL) 1.0 (>0.05) ND
Paclitaxel (0.085µg/mL) GF120918 (0.6µg/mL) 1.7 (<0.01) ND Nanovskaya et al. (2005)
Methadone (0.2µg/mL) GF120918 (0.6µg/mL) 1.3 (<0.01) ND
MRPs Talinolol (0.29µg/mL) Probenecidc (2.9µg/mL) 1.2 (<0.05) ND May et al. (2008)
Saquinavir (6.7µg/mL) MK-571 (26.9µg/mL) ND 0.9 (>0.05) Rahi et al. (2009)
Probenecidc (14.3µg/mL) ND 0.8 (>0.05)
OCTs Metformin (2.0µg/mL) Cimetidine (100µg/mL) 1.3 (>0.05) 1.3 (>0.05) Tertti et al. (2010)
The methodology for calculation of maternal-to-fetal and fetal-to-maternal transfer varied across studies. aValues are normalized to changes in the transfer of markers
for passive diffusion. bAlso an MRP1 and OATPs inhibitor. cAlso an OATPs inhibitor. ND, not determined.
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saquinavir, a substrate for both P-gp and MRPs (Park and Sinko,
2005). However, in a later study, the MRP1 inhibitor probenecid
did not affect the trans-placental transfer of saquinavir (Rahi et al.,
2009; Table 1).
Multidrug resistance protein 2 is expressed at the apical human
syncytiotrophoblast membrane (St-Pierre et al., 2000; Figure 1).
A functional role of MRP2 in the placental barrier for xenobi-
otics was demonstrated by May and coworkers. Slight but sta-
tistically significant increases in maternal-fetal permeability of
talinolol were demonstrated in the presence of the MRP2 inhibitor,
probenecid, and the non-specific inhibitor, verapamil, but not by
the P-gp inhibitor PSC833 (May et al., 2008; Table 1).
Transporters of the solute carrier superfamily
Solute carrier transporters known to be expressed in the pla-
centa and involved in trans-placental drug transfer include organic
anion transporting polypeptides, organic anion transporters,
organic cation transporters (OCTs), monoamine transporters,
and equilibrative nucleoside transporters. Among these, currently
available data point mostly to potential DDIs which involve OCTs
or monoamine transporters.
Organic cation transporters. Organic cation transporters
include the potential-sensitive OCTs and the proton gradient-
driven OCTNs. Among the human OCTs, only OCT3 (SLC22A3)
is expressed in the human placenta, at the basal membrane of tro-
phoblast cells (St-Pierre et al., 2002; Figure 1). In addition, both
OCTN1 and OCTN2 are expressed at the maternal-facing mem-
brane of syncytiotrophoblasts, where they likely facilitate substrate
transfer from the maternal to the fetal side (Ganapathy and Prasad,
2005; Figure 1). OCTN 1 and 2 substrates include verapamil and
quinidine (Ciarimboli, 2011). It has been suggested that met-
formin transport across the placenta is mediated by OCTs (Kovo
et al., 2008). However, a later study showed lack of significant
effect of the OCT inhibitor cimetidine on the placental transfer of
metformin (Tertti et al., 2010; Table 1).
Monoamine transporters. The serotonin transporter (SERT)
and the norepinephrine transporter (NET), which are responsible
for the neuronal uptake of these monoamines, are expressed on
the maternal-facing membrane of syncytiotrophoblasts (Figure 1;
Ganapathy, 2011). Amphetamines, but not cocaine, are substrates
for the two transporters. A variety of antidepressants are estab-
lished inhibitors of monoamine transporters and their impact on
placental SERT and NET has yet to be clarified (Ganapathy, 2011).
IMPACT OF MATERNAL PHARMACOKINETICS ON FETAL
EXPOSURE TO DRUGS
Fetal exposure to medications depends not only on their transfer
across the placenta but also on their pharmacokinetics in both
mother and fetus. As pregnancy precedes, related physiological
changes, including changes in organ blood flow, hepatic drug-
metabolizing enzyme activity (Anderson, 2005), and renal elimi-
nation (Hebert et al., 2008; Eyal et al., 2010) may affect the overall
amount of drugs and their metabolites that cross the placenta.
Moreover, if placental transfer mechanisms are saturable, as in
the case of metformin (Kovo et al., 2008), such changes over
gestation could result in non-linear trans-placental transfer kinet-
ics and alter the magnitude of placental-mediated DDIs. Finally,
altered fetal exposure to medications may be caused by simulta-
neous interactions among drugs at multiple maternal and fetal
organs (e.g., inhibition of drug-metabolizing enzymes or trans-
porters in maternal tissues, the placenta, and potentially fetal
tissues themselves).
CONCLUSION
The majority of currently reported DDI at the placenta involve
ABC efflux transporters, in particular P-gp. Based on studies in
rodents, it has been assumed that such interactions can signif-
icantly affect fetal exposure to medications. Studies in isolated
human placenta suggest that efflux transporters are indeed impor-
tant in limiting drug delivery to the fetus. However, the magnitude
of such interactions appears to be modest, and overall lesser com-
pared to those observed at the blood-brain barrier. To our knowl-
edge, the impact of such interactions in terms of fetal outcomes in
humans has not been reported so far. Nevertheless, for substrates
such as lopinavir, P-gp inhibition can significantly affect fetal expo-
sure. Whether P-gp inhibition can enhance fetal toxicity from
drugs with narrow therapeutic index (e.g., doxorubicin) is cur-
rently unknown. It is still not clear whether the substrate-inhibitor
combinations studied so far represent other drug combinations,
and whether the magnitude of interaction that occurs in term pla-
centae is representative of various disease conditions and earlier
gestational ages. For example, because P-gp expression decreases
during pregnancy, the effect of its inhibition may be greater in
early gestation, during fetal organogenesis. In addition, interac-
tions may be mediated by yet unidentified transporters and other
components of the placenta. It should be also kept in mind that
drugs can potentially affect the delivery of hormones and nutri-
ents to the fetus. Therefore, additional data are needed with other
substrates and inhibitors for optimization of drug choice. Manip-
ulation of placental transporters has been suggested as means
to control fetal exposure to medications and enhance the effi-
cacy of pharmacotherapy in the fetus (Ito, 2001; Syme et al.,
2004). However, more studies are required before such interven-
tions can be recommended. Future studies should address the
potential sources for the different results obtained in humans vs.
rodents and establish models for prediction of placental-mediated
DDIs. Importantly, incorporating measurements of drug concen-
trations in maternal and cord plasma in longitudinal studies in
pregnant women and their children may improve our under-
standing of the outcomes associated with polytherapy during
pregnancy.
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